Skip to main content
Researchers evaluate AbbVie's hepatitis drug in HCV patients with CKD

Patients with hepatitis C genotype 1b and chronic kidney disease who received AbbVie's Viekirax, or ombitasvir, paritaprevir and ritonavir, had similar rates of rapid virologic response, end of treatment response and sustained virologic response, compared with those without CKD, researchers reported in Hepatology Research. The findings also showed similar prevalence of treatment-emergent adverse events between both groups.

Full Story: